ArticleHeliyon2024
Role of Nrf2/HO-1 and cytoglobin signaling in the protective effect of indole-3-acetic acid and chenodeoxycholic acid against kidney injury induced by valproate.
Article in Heliyon, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Article
- The Gut Microbial Metabolite Indole-3-Acetic Acid Reprograms Systemic Homeostasis and Ameliorates IBD-Associated Cachexia Independent of Food Intake.International journal of molecular sciences · 2025Article
- Gut microbiota-derived indole-3-acetic acid ameliorates calcium oxalate renal stone formation via AHR/NF‑κB axis.Urolithiasis · 2025Article
- Multifaceted Role of Microbiota-Derived Indole-3-Acetic Acid in Human Diseases and Its Potential Clinical Application.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2025Review
- Indole-3-acetic acid and chenodeoxycholic acid attenuate TLR4/NF-κB signaling and endoplasmic reticulum stress in valproic acid-induced neurotoxicity.Frontiers in pharmacology · 2025Article
- Acetylation in renal physiology and pathophysiology.Frontiers in pharmacology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Purpose: Valproate (VPA) is an antiepileptic drug widely used to treat various psychiatric and neurological disorders. Although its use is generally considered safe, chronic administration may lead to kidney injury. The mechanisms underlying VPA kidney toxicity are not entirely explored. This has prompted our investigation into a novel molecular signaling pathway involved in VPA-induced kidney injury and the exploration of strategies to ameliorate this toxicity using indole-3-acetic acid (IAA) and chenodeoxycholic acid (CDCA). Methods: Rats were divided as follows: group I (control); group II (VPA group), where rats were administered VPA (500 mg/kg, i.p.) daily to induce kidney injury for 3 weeks; and groups III and IV, where rats were orally treated with either IAA (40 mg/kg) or CDCA (90 mg/kg), respectively, 1h post-VPA dose, for 3 weeks. The effects of these compounds on kidney tissues were evaluated with a focus on their antioxidant and anti-inflammatory properties using biochemical, histopathological, and immunohistochemical analyses. Results: VPA caused a significant reduction in renal glutathione (GSH) and heme oxygenase-1 (HO-1) levels, and superoxide dismutase (SOD) activity, along with a significant elevation in malondialdehyde (MDA) levels. Similarly, tumor necrosis factor-α (TNF-α), interleukin-1beta (IL-1β), and interleukin-6 (IL-6) levels were significantly increased. Immunohistochemical analysis demonstrated a significant decline in the immunoreactivity of nuclear factor erythroid 2-related factor (Nrf2) and cytoglobin antigens in renal cells. However, administration of either IAA or CDCA significantly ameliorated these altered parameters, including Nrf2/HO-1 and cytoglobin levels. Conclusion: IAA and CDCA alleviated the kidney injury induced by VPA via downregulating the inflammatory response and upregulating the antioxidant capacity in renal tissue.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.